Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PARADI MIRMIRANI

Allopathic & Osteopathic Physicians Dermatology

NPI
1780758086
CMS profile
528173
Location
VALLEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$5,123.32

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,100.00 2
Food and Beverage $23.32 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
SUN PHARMACEUTICAL INDUSTRIES INC. $5,100.00 2
PFIZER INC. $23.32 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PARADI MIRMIRANI

NPI 1780758086 · CMS profile ID 528173

Allopathic & Osteopathic Physicians / Dermatology

VALLEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780758086?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780758086?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780758086?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1780758086?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $5,123.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $1,600.0010/29/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1154913402 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $3,500.0010/18/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1154913400 CMS
PFIZER INC. $23.3204/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131412721 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,190.07 6
PY2021 $5,100.00 1
PY2022 $3,726.42 4
PY2024 $5,123.32 3
PY2025 $16,185.62 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $479,737.84 282
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $768,360.94 287
PY2023 Recipient $5,740.00 5
PY2023 Principal investigator $318,195.33 82
PY2022 Recipient $1,600.00 3
PY2022 Principal investigator $29,594.10 8
PY2021 Principal investigator $84,014.35 20
PY2020 Principal investigator $176,397.66 37
PY2019 Principal investigator $77,460.50 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

282 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,050.00 12/29/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433193
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 12/24/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433181
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,100.00 12/24/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433186
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $450.00 12/24/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433190
Principal investigator 1 Incyte Corporation $1,758.40 12/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484815
Principal investigator 1 Incyte Corporation $2,198.00 12/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484821
Principal investigator 1 Incyte Corporation $3,525.40 12/08/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484440
Principal investigator 1 Incyte Corporation $750.00 12/08/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484520
Principal investigator 1 Incyte Corporation $1,500.00 12/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484509
Principal investigator 1 Incyte Corporation $140.00 12/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484628
Principal investigator 1 Incyte Corporation $1,200.00 12/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484828
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $150.00 12/04/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433167
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $300.00 12/04/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433173
Principal investigator 1 Incyte Corporation $8.48 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484430
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484456
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484462
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484491
Principal investigator 1 Incyte Corporation $114.50 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484504
Principal investigator 1 Incyte Corporation $98.72 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484515
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484526
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484583
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484590
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484596
Principal investigator 1 Incyte Corporation $32.88 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484602
Principal investigator 1 Incyte Corporation $64.72 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484758
Principal investigator 1 Incyte Corporation $28.44 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484775
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484809
Principal investigator 1 Incyte Corporation $2,531.00 11/24/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484541
Principal investigator 1 Incyte Corporation $1,982.50 11/24/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484837
Principal investigator 1 Incyte Corporation $70.00 11/19/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484451
Principal investigator 1 Incyte Corporation $250.00 11/19/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484802
Principal investigator 1 Incyte Corporation $2,159.20 11/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484705
Principal investigator 1 Incyte Corporation $2,699.00 11/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484712
Principal investigator 1 Incyte Corporation $2,500.00 11/07/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484435
Principal investigator 1 Incyte Corporation $500.00 11/07/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484446
Principal investigator 1 Incyte Corporation $9,560.00 11/07/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484497
Principal investigator 1 Incyte Corporation $3,500.00 11/07/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484568
Principal investigator 1 Incyte Corporation $4,000.00 11/07/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484575
Principal investigator 1 Incyte Corporation $70.00 11/07/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484609
Principal investigator 1 Incyte Corporation $1,875.00 11/07/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484621
Principal investigator 1 Incyte Corporation $49.36 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484474
Principal investigator 1 Incyte Corporation $49.36 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484480
Principal investigator 1 Incyte Corporation $49.36 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484486
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484633
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484639
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484644
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484652
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484657
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484663
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484669
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484675
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484681
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484688
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484692
Principal investigator 1 Incyte Corporation $16.44 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484700
Principal investigator 1 Incyte Corporation $9.72 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484719
Principal investigator 1 Incyte Corporation $9.72 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484724
Principal investigator 1 Incyte Corporation $9.72 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484731
Principal investigator 1 Incyte Corporation $22.90 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484736
Principal investigator 1 Incyte Corporation $22.90 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484742
Principal investigator 1 Incyte Corporation $22.90 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484748
Principal investigator 1 Incyte Corporation $406.20 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484844
Principal investigator 1 Incyte Corporation $406.20 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484850
Principal investigator 1 Incyte Corporation $0.62 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484856
Principal investigator 1 Incyte Corporation $0.62 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484863
Principal investigator 1 Incyte Corporation $0.62 11/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484869
Principal investigator 1 Incyte Corporation $1,200.00 11/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484834
Principal investigator 1 Incyte Corporation $70.00 10/20/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484418
Principal investigator 1 Incyte Corporation $496.90 10/20/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484560
Principal investigator 1 Incyte Corporation $2,531.00 10/20/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484786
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,778.90 10/10/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433159
Principal investigator 1 Incyte Corporation $1,710.20 10/08/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484467
Principal investigator 1 Incyte Corporation $2,680.00 10/08/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484752
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $19,663.02 10/08/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433154
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,465.00 10/07/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433149
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484423
Principal investigator 1 Incyte Corporation $560.00 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484532
Principal investigator 1 Incyte Corporation $2,637.90 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484548
Principal investigator 1 Incyte Corporation $684.00 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484554
Principal investigator 1 Incyte Corporation $550.00 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484614
Principal investigator 1 Incyte Corporation $600.00 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484780
Principal investigator 1 Incyte Corporation $200.00 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484791
Principal investigator 1 Incyte Corporation $750.00 10/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484875
Principal investigator 1 Incyte Corporation $54.76 10/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484764
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484769
Principal investigator 1 Incyte Corporation $22.90 10/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484797
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,126.71 09/26/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433144
Principal investigator 1 Incyte Corporation $750.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484196
Principal investigator 1 Incyte Corporation $140.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484208
Principal investigator 1 Incyte Corporation $100.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484215
Principal investigator 1 Incyte Corporation $1,250.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484221
Principal investigator 1 Incyte Corporation $560.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484228
Principal investigator 1 Incyte Corporation $300.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484233
Principal investigator 1 Incyte Corporation $750.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484240
Principal investigator 1 Incyte Corporation $100.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484257
Principal investigator 1 Incyte Corporation $242.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484319
Principal investigator 1 Incyte Corporation $242.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484326
Principal investigator 1 Incyte Corporation $175.00 09/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484345
Principal investigator 1 Incyte Corporation $750.00 09/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484191
Principal investigator 1 Incyte Corporation $250.00 09/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484252
Principal investigator 1 Incyte Corporation $70.00 09/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484264
Principal investigator 1 Incyte Corporation $35.00 09/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484333
Principal investigator 1 Incyte Corporation $1,874.10 09/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484168
Principal investigator 1 Incyte Corporation $2,699.00 09/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484338
Principal investigator 1 Incyte Corporation $2,680.00 09/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484412
Principal investigator 1 Incyte Corporation $105.00 09/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484174
Principal investigator 1 Incyte Corporation $500.00 09/05/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484373
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,525.00 09/02/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433139
Principal investigator 1 Incyte Corporation $105.00 08/22/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484315
Principal investigator 1 Incyte Corporation $2,384.80 08/20/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484136
Principal investigator 1 Incyte Corporation $1,500.00 08/20/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484142
Principal investigator 1 Incyte Corporation $2,531.00 08/20/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484399
Principal investigator 1 Incyte Corporation $250.00 08/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484178
Principal investigator 1 Incyte Corporation $2,732.00 08/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484184
Principal investigator 1 Incyte Corporation $2,680.00 08/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484201
Principal investigator 1 Incyte Corporation $175.00 08/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484388
Principal investigator 1 Incyte Corporation $100.00 08/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484406
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $65.00 08/01/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433124
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 08/01/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433128
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 08/01/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433130
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $390.00 07/28/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433120
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,634.00 07/18/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433116
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,763.87 07/15/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433112
Principal investigator 1 Incyte Corporation $1,654.30 07/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484148
Principal investigator 1 Incyte Corporation $2,699.00 07/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484154
Principal investigator 1 Incyte Corporation $2,198.00 07/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484162
Principal investigator 1 Incyte Corporation $2,680.00 07/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484395
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484246
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484269
Principal investigator 1 Incyte Corporation $74.04 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484276
Principal investigator 1 Incyte Corporation $6.36 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484284
Principal investigator 1 Incyte Corporation $14.58 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484290
Principal investigator 1 Incyte Corporation $97.08 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484296
Principal investigator 1 Incyte Corporation $113.26 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484302
Principal investigator 1 Incyte Corporation $14.84 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484308
Principal investigator 1 Incyte Corporation $57.54 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484349
Principal investigator 1 Incyte Corporation $57.54 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484354
Principal investigator 1 Incyte Corporation $57.54 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484361
Principal investigator 1 Incyte Corporation $57.54 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484366
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484377
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484382
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 07/01/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433108
Principal investigator 1 Incyte Corporation $2,531.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483685
Principal investigator 1 Incyte Corporation $2,626.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483691
Principal investigator 1 Incyte Corporation $2,626.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483695
Principal investigator 1 Incyte Corporation $552.50 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483699
Principal investigator 1 Incyte Corporation $2,484.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483705
Principal investigator 1 Incyte Corporation $751.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483712
Principal investigator 1 Incyte Corporation $751.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484016
Principal investigator 1 Incyte Corporation $2,531.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484022
Principal investigator 1 Incyte Corporation $2,531.00 06/25/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484028
Principal investigator 1 Incyte Corporation $1,608.00 06/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483937
Principal investigator 1 Incyte Corporation $2,680.00 06/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483943
Principal investigator 1 Incyte Corporation $2,680.00 06/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483951
Principal investigator 1 Incyte Corporation $2,680.00 06/11/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483957
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,498.00 06/05/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433103
Principal investigator 1 Incyte Corporation $97.08 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483739
Principal investigator 1 Incyte Corporation $22.90 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483763
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483848
Principal investigator 1 Incyte Corporation $74.04 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483854
Principal investigator 1 Incyte Corporation $57.25 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483867
Principal investigator 1 Incyte Corporation $45.80 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483873
Principal investigator 1 Incyte Corporation $24.72 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483879
Principal investigator 1 Incyte Corporation $12.15 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483885
Principal investigator 1 Incyte Corporation $6.18 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483891
Principal investigator 1 Incyte Corporation $6.18 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483898
Principal investigator 1 Incyte Corporation $947.80 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483904
Principal investigator 1 Incyte Corporation $80.90 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483910
Principal investigator 1 Incyte Corporation $57.25 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483916
Principal investigator 1 Incyte Corporation $12.72 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483928
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484040
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484046
Principal investigator 1 Incyte Corporation $49.32 06/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484052
Principal investigator 1 Incyte Corporation $2,680.00 05/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483644
Principal investigator 1 Incyte Corporation $1,710.20 05/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483652
Principal investigator 1 Incyte Corporation $14.58 05/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483812
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483824
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483830
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484064
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484070
Principal investigator 1 PFIZER INC. $32.00 04/25/2025 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228709700
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $325.00 04/15/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433087
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,520.30 04/15/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433091
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,781.78 04/11/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433082
Principal investigator 1 Incyte Corporation $2,680.00 04/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483627
Principal investigator 1 Incyte Corporation $2,828.00 04/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483633
Principal investigator 1 Incyte Corporation $2,828.00 04/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483639
Principal investigator 1 Incyte Corporation $2,699.00 04/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483922
Principal investigator 1 Incyte Corporation $2,198.00 04/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484004
Principal investigator 1 Incyte Corporation $1,088.70 04/09/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484058
Principal investigator 1 Eli Lilly and Company $18,265.60 04/08/2025 Covered Recipient Teaching Hospital
KFH - SANTA CLARA
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187872315
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $830.00 04/07/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433073
Principal investigator 1 Incyte Corporation $84.80 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483656
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483662
Principal investigator 1 Incyte Corporation $106.00 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483670
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483676
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483718
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483724
Principal investigator 1 Incyte Corporation $14.58 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483730
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483735
Principal investigator 1 Incyte Corporation $6.36 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483746
Principal investigator 1 Incyte Corporation $4.24 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483751
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483757
Principal investigator 1 Incyte Corporation $22.90 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483769
Principal investigator 1 Incyte Corporation $32.36 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483775
Principal investigator 1 Incyte Corporation $48.54 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483782
Principal investigator 1 Incyte Corporation $12.15 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483788
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483794
Principal investigator 1 Incyte Corporation $0.93 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483800
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483806
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483818
Principal investigator 1 Incyte Corporation $1.24 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483836
Principal investigator 1 Incyte Corporation $22.90 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483842
Principal investigator 1 Incyte Corporation $98.72 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483861
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483963
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483969
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483981
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483986
Principal investigator 1 Incyte Corporation $311.35 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483992
Principal investigator 1 Incyte Corporation $947.80 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483998
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484010
Principal investigator 1 Incyte Corporation $137.80 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484034
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484075
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484081
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484090
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484096
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484102
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484108
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484115
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484121
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484126
Principal investigator 1 Incyte Corporation $24.66 04/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240484131
Principal investigator 1 Incyte Corporation $2,699.00 03/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483423
Principal investigator 1 Incyte Corporation $2,680.00 03/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483430
Principal investigator 1 Incyte Corporation $2,680.00 03/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483436
Principal investigator 1 Incyte Corporation $2,747.00 03/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483451
Principal investigator 1 Incyte Corporation $2,747.00 03/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483457
Principal investigator 1 Incyte Corporation $1,073.80 03/12/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483597
Principal investigator 1 Incyte Corporation $48.54 03/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483543
Principal investigator 1 Incyte Corporation $0.93 03/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483550
Principal investigator 1 Incyte Corporation $74.04 03/03/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483556
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,657.40 02/26/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433069
Principal investigator 1 Amgen Inc. $10,867.57 02/22/2025 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246638404
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $700.00 02/19/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433050
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,024.00 02/19/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433055
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,750.00 02/19/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433059
Principal investigator 1 Incyte Corporation $2,680.00 02/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483441
Principal investigator 1 Incyte Corporation $1,318.10 02/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483447
Principal investigator 1 Incyte Corporation $2,699.00 02/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483462
Principal investigator 1 Incyte Corporation $2,780.00 02/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483585
Principal investigator 1 Incyte Corporation $2,780.00 02/10/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483591
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,223.00 02/07/2025 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246433046
Principal investigator 1 Incyte Corporation $315.00 01/24/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483373
Principal investigator 1 Incyte Corporation $1,500.00 01/24/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483380
Principal investigator 1 Incyte Corporation $2,680.00 01/15/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483387
Principal investigator 1 Incyte Corporation $680.40 01/15/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483391
Principal investigator 1 Incyte Corporation $3,150.00 01/15/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483398
Principal investigator 1 Incyte Corporation $3,150.00 01/15/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483404
Principal investigator 1 Incyte Corporation $2,828.00 01/15/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483410
Principal investigator 1 Incyte Corporation $2,828.00 01/15/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483417
Principal investigator 1 Incyte Corporation $2,680.00 01/15/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483601
Principal investigator 1 Amgen Inc. $95,519.32 01/03/2025 Covered Recipient Teaching Hospital
Kfh - San Francisco
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246638398
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483470
Principal investigator 1 Incyte Corporation $254.40 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483477
Principal investigator 1 Incyte Corporation $169.60 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483482
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483488
Principal investigator 1 Incyte Corporation $68.90 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483494
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483500
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483506
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483511
Principal investigator 1 Incyte Corporation $58.30 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483517
Principal investigator 1 Incyte Corporation $148.40 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483524
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483529
Principal investigator 1 Incyte Corporation $26.50 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483536
Principal investigator 1 Incyte Corporation $10.60 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483562
Principal investigator 1 Incyte Corporation $125.95 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483568
Principal investigator 1 Incyte Corporation $265.00 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483573
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483579
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483607
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483613
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483617
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Covered Recipient Teaching Hospital
Kfh - Oakland
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240483622